Literature DB >> 19181757

The effect of daily administration of IL-18 on cardiac structure and function.

A Platis1, Q Yu, D Moore, Ev Khojeini, P Tsau, Df Larson.   

Abstract

Recently, the cytokine Interleukin-18 (IL-18) has been shown to be increased as a result of cardiac surgery. Elevated IL-18 has been associated with neurological dysfunction, systemic inflammatory response syndrome (SIRS), and multiple organ dysfunction syndrome (MODS) post open-heart surgery. The intent of the study contained herein was to determine the effect of IL-18 administration on cardiac function and structure. Eight C57BL/6 female mice were treated daily with 0.5microg/mouse of recombinant IL-18 for 7 days. Long axis echocardiography (ECHO) measurements of the anatomical and hemodynamic function of the heart for all mice were studied 24h after the last dose. The left ventricular wet weights increased from 84 +/- 1 to 93 +/- 3 mg when comparing the placebo (n = 8) with the IL-18 groups, respectively (p = 0.01). With ECHO analysis, IL-18 significantly increased left ventricular (LV) mass, the left atrium dimensions (LA), and the left ventricular posterior wall thickness (LVPW) over the 8-day time period (p < 0.01). There was a 5-fold increase in interstitial cardiac collagen content and a 30% increase in myocyte size in the IL-18 compared with the control groups (p < 0.01). Administration of IL-18 appears to induce interstitial fibrosis and myocyte hypertrophy, resulting in increased ventricular stiffness. Thus, increased IL-18 during and post open-heart surgical procedures may induce left ventricular diastolic dysfunction and affect post-operative outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19181757     DOI: 10.1177/0267659108101511

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  24 in total

1.  β2 adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrophy in vitro and myocardial hypertrophy in vivo.

Authors:  David R Murray; Srinivas Mummidi; Anthony J Valente; Tadashi Yoshida; Naveen K Somanna; Patrice Delafontaine; Charles A Dinarello; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2011-10-08       Impact factor: 5.000

2.  Cytokines profile of reverse cardiac remodeling following transcatheter aortic valve replacement.

Authors:  Juyong Brian Kim; Yukari Kobayashi; Tatiana Kuznetsova; Kegan J Moneghetti; Daniel A Brenner; Ryan O'Malley; Catherine Dao; Joseph C Wu; Michael Fischbein; D Craig Miller; Alan C Yeung; David Liang; Francois Haddad; William F Fearon
Journal:  Int J Cardiol       Date:  2018-11-01       Impact factor: 4.164

3.  Anti-inflammatory activities of hepatocyte growth factor in post-ischemic heart failure.

Authors:  Shu-Ling Rong; Xiao-Lin Wang; Yi-Cheng Wang; Huan Wu; Xue-Dong Zhou; Ze-Kun Wang; Yu-Chuan Wang; Cun-Shui Xue; Bao Li; Dong-Lai Gao
Journal:  Acta Pharmacol Sin       Date:  2018-05-24       Impact factor: 6.150

Review 4.  Inflammation in nonischemic heart disease: initiation by cardiomyocyte CaMKII and NLRP3 inflammasome signaling.

Authors:  Takeshi Suetomi; Shigeki Miyamoto; Joan Heller Brown
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-23       Impact factor: 4.733

5.  Role of Interleukin-1 in Radiation-Induced Cardiomyopathy.

Authors:  Eleonora Mezzaroma; Ross B Mikkelsen; Stefano Toldo; Adolfo G Mauro; Khushboo Sharma; Carlo Marchetti; Asim Alam; Benjamin W Van Tassell; David A Gewirtz; Antonio Abbate
Journal:  Mol Med       Date:  2015-03-26       Impact factor: 6.354

6.  Effects of interleukin-18 on cardiac fibroblast function and gene expression.

Authors:  Charity Fix; Kellie Bingham; Wayne Carver
Journal:  Cytokine       Date:  2010-11-02       Impact factor: 3.861

7.  Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18.

Authors:  Anthony J Valente; Tadashi Yoshida; Subramanyam N Murthy; Siva S V P Sakamuri; Masato Katsuyama; Robert A Clark; Patrice Delafontaine; Bysani Chandrasekar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-05-25       Impact factor: 4.733

Review 8.  Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.

Authors:  Laura C O'Brien; Eleonora Mezzaroma; Benjamin W Van Tassell; Carlo Marchetti; Salvatore Carbone; Antonio Abbate; Stefano Toldo
Journal:  Mol Med       Date:  2014-06-12       Impact factor: 6.354

9.  Genetic ablation of interleukin-18 does not attenuate hypobaric hypoxia-induced right ventricular hypertrophy.

Authors:  Danielle R Bruns; Peter M Buttrick; Lori A Walker
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-01-08       Impact factor: 5.464

10.  Pressure overload induces IL-18 and IL-18R expression, but markedly suppresses IL-18BP expression in a rabbit model. IL-18 potentiates TNF-α-induced cardiomyocyte death.

Authors:  Tadashi Yoshida; Ingeborg Friehs; Srinivas Mummidi; Pedro J del Nido; Solange Addulnour-Nakhoul; Patrice Delafontaine; Anthony J Valente; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2014-08-07       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.